Qube Research & Technologies (QRT)
MRTX

Qube Research & Technologies (QRT)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,374
Closed -$1.43M – 5017
2023
Q4 		$1.43M Buy
+24,374
New +$1.37M ﹤0.01% 1709
2022
Q4 		– Sell
-56,742
Closed -$3.96M – 3134
2022
Q3 		$3.96M Buy
56,742
+40,038
+240% +$2.96M 0.02% 689
2022
Q2 		$1.12M Sell
16,704
-22,011
-57% -$1.4M 0.01% 1054
2022
Q1 		$3.18M Buy
+38,715
New +$3.96M 0.03% 650
2021
Q3 		– Sell
-21,964
Closed -$3.55M – 2924
2021
Q2 		$3.55M Buy
+21,964
New +$3.53M 0.04% 515
2020
Q4 		– Sell
-3,494
Closed -$580K – 2296
2020
Q3 		$580K Buy
+3,494
New +$478K 0.01% 985

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MRTX Position: Q1 2024 in Review

Qube Research & Technologies (QRT) sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 24,374 shares — an estimated $1.43M sold.

Qube Research & Technologies (QRT) first reported a position in MRTX in Q3 2020 and held it in 6 quarters. The position peaked at $3.96M in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Qube Research & Technologies (QRT) reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 24,374 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.43M.
  • Qube Research & Technologies (QRT) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
  • Qube Research & Technologies (QRT)'s Mirati Therapeutics, Inc. Common Stock position peaked at $3.96M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2024, filed 14 May 2024.